Sarepta Therapeutics (SRPT)
(Delayed Data from NSDQ)
$140.56 USD
-0.87 (-0.62%)
Updated Aug 23, 2024 04:00 PM ET
After-Market: $140.56 0.00 (0.00%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth F Momentum F VGM
Sarepta Therapeutics (SRPT) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$196.94 | $235.00 | $152.00 | 39.25% |
Price Target
Based on short-term price targets offered by 17 analysts, the average price target for Sarepta Therapeutics comes to $196.94. The forecasts range from a low of $152.00 to a high of $235.00. The average price target represents an increase of 39.25% from the last closing price of $141.43.
Analyst Price Targets (17)
Broker Rating
Sarepta Therapeutics currently has an average brokerage recommendation (ABR) of 1.32 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by 19 brokerage firms. The current ABR compares to an ABR of 1.47 a month ago based on 19 recommendations.
Of the 19 recommendations deriving the current ABR, 15 are Strong Buy and two are Buy. Strong Buy and Buy respectively account for 78.95% and 10.53% of all recommendations. A month ago, Strong Buy made up 73.68%, while Buy represented 5.26%.
Broker Rating Breakdown
![Broker Rating Visualization](https://widget3.zacks.com/images/charts/bar/brokerage/bar/SRPT.png)
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 15 | 15 | 14 | 14 | 16 |
Buy | 2 | 2 | 1 | 1 | 1 |
Hold | 2 | 2 | 4 | 4 | 3 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.32 | 1.32 | 1.47 | 1.47 | 1.35 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
8/9/2024 | UBS | Colin N Bristow | Strong Buy | Strong Buy |
8/8/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
8/8/2024 | William Blair | Timothy F Lugo | Strong Buy | Strong Buy |
8/8/2024 | Evercore Partners | Gavin Clark-Gartner | Hold | Strong Buy |
8/7/2024 | SVB Securities | Joseph P Schwartz | Strong Buy | Strong Buy |
7/29/2024 | Not Identified | Not Identified | Hold | Moderate Buy |
7/8/2024 | Mizuho SecuritiesUSA | Uy D Ear | Strong Buy | Strong Buy |
6/26/2024 | Not Identified | Not Identified | Strong Buy | Hold |
6/21/2024 | Piper Sandler | Biren Amin | Strong Buy | Strong Buy |
6/21/2024 | Robert W. Baird & Co. | Brian P Skorney | Strong Buy | Strong Buy |
6/21/2024 | Not Identified | Not Identified | Strong Buy | Strong Buy |
6/21/2024 | Cantor Fitzgerald & Co | Kristen Kluska | Hold | Hold |
6/14/2024 | BMO Capital Markets | Kostas Biliouris | Strong Buy | Strong Buy |
5/2/2024 | Needham & Company | Gil J Blum | Moderate Buy | Moderate Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
3/15/2024 | Goldman Sachs | Salveen Richter | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.32 |
ABR (Last week) | 1.32 |
# of Recs in ABR | 19 |
Average Target Price | $196.94 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 81 of 253 |
Current Quarter EPS Est: | -0.06 |